RT Journal Article
T1 Vardenafil Improves Penile Erection in Type 2 Diabetes Mellitus Patients with Erectile Dysfunction: Role of Tropomyosin
A1 Zamorano León, José Javier
A1 Olivier, Carlos
A1 Heras Jiménez, Natalia De Las
A1 Mateos Cáceres, Petra
A1 Rodríguez Sierra, Pablo
A1 Martín Palacios, Naihara
A1 Modrego, Javier
A1 Macaya Miguel, Carlos
A1 López Farre, Antonio José
AB Introduction. Evidences have been suggested that phosphodiesterase type 5 (PDE5) inhibition promotesvasculoprotective benefits in patients with cardiovascular diseases.Aim. The aim of this study is to analyze the systemic effect of PDE5 inhibition in type 2 diabetes mellitus patientswith erectile dysfunction (ED) determining changes in the expression levels of plasma proteins.Methods. Seventeen patients with controlled type 2 diabetes mellitus and ED were included in the study. Patientsreceived vardenafil hydrochloride 20 mg on demand during 12 weeks. At the beginning and 12 weeks after vardenafiladministration, plasma samples were collected and analyzed using proteomics.Main Outcome Measures. International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) andplasma protein expression before and after vardenafil administration. Nitrate/nitrite release, PDE5, and solubleguanylate cyclase (sGC) expression and cyclic guanosine monophosphate (cGMP) content in cultured bovine aorticendothelial cells (BAECs).Results. The IIEF-EFD score was markedly improved after 12 weeks of vardenafil administration. Plasma levels ofalpha 1-antitrypsin isotypes 4 and 6 and β-tropomyosin were decreased, whereas apolipoprotein AI isoype 5 wasincreased 12 weeks after vardenafil administration. Only β-tropomyosin plasma levels were inversely correlated withIIEF-EFD score. Tropomyosin has been added to cultured BAECs and after 24 hours reduced the protein expressionlevel of sGC-β1 subunit and decreased the cGMP content. Tropomyosin did not modify PDE5 expression and nitricoxide release in BAECs as compared with control BAECs. Vardenafil (10 μg/mL) did not modify sGC-β1 subunitexpression in tropomyosin + vardenafil-incubated BAECs; however, vardenafil significantly reversed the reduction ofcGMP content induced by tropomyosin.Conclusion. Vardenafil administration improved erectile functionality in controlled type 2 diabetes mellitus patientswith ED, which was associated with reduction of circulating plasma β-tropomyosin levels. Tropomyosin affected byitself the cGMP generating system suggesting a possible new mechanism involved in ED. Vardenafil reversed thereduction effect of cGMP content elicited by tropomyosin in BAECs. Zamorano-León JJ, Olivier C, de las HerasN, Mateos-Cáceres PJ, Brime Menéndez R,Rodríguez-Sierra P, Martín Palacios N, Manso LSJ, Modrego J,Segura A, Macaya C, and López-Farré AJ. Vardenafil improves penile erection in type 2 diabetes mellituspatients with erectile dysfunction: Role of tropomyosin. J Sex Med 2013;10:3110–3120.
PB Elsevier
SN 1743-6095
YR 2013
FD 2013-07-01
LK https://hdl.handle.net/20.500.14352/99284
UL https://hdl.handle.net/20.500.14352/99284
LA eng
NO Zamorano-León JJ, Olivier C, de Las Heras N, Mateos-Cáceres PJ, Brime Menéndez R, Rodríguez-Sierra P, Martín Palacios N, Manso LS, Modrego J, Segura A, Macaya C, López-Farré AJ. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin. J Sex Med. 2013 Dec;10(12):3110-20. doi: 10.1111/jsm.12324
NO Unión Europea
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 6 oct 2024